Meridian
Pharma & biotech signals
Log in

Signals

Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.

Showing 41–60 of 631 signals

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Company disclosure·news.bms.com·Aug 13, 2026·Approval·High materiality
CompaniesBristol Myers SquibbAssetsZENBEXUSdaratumumabhyaluronidase-fihjdexamethasoneDiseasesmultiple myeloma
6 sources — primary and 5 also reporting
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Primary·news.bms.com·Aug 13, 2026
FDA Approves First CELMoD Drug for Multiple Myeloma
Trade press·medpagetoday.com·Aug 13, 2026
FDA: OK para Zenbexus de BMS
Trade press·pharmabiz.net·Aug 13, 2026
BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod
Trade press·fiercepharma.com·Aug 14, 2026
BMS welcomes new multiple myeloma drug as generics batter current portfolio
Trade press·biospace.com·Aug 14, 2026
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Company disclosure·prnewswire.com·Aug 19, 2026

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Company disclosure·globenewswire.com·Aug 19, 2026·Commercial·High materiality
CompaniesNovartis
3 sources — primary and 2 also reporting
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Primary·globenewswire.com·Aug 19, 2026
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Company disclosure·novartis.com·Aug 19, 2026
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Trade press·biospace.com·Aug 19, 2026

Orpathys plus Tagrisso shows survival benefit in lung cancer

Trade press·pharmatimes.com·Aug 19, 2026·Trial readout·High materiality
CompaniesHUTCHMEDAstraZenecaAssetsOrpathysTagrissoDiseasesEGFR-mutated non-small cell lung cancer
Related coverage (2) — shares extracted facts, not the same cluster
AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
fiercepharma.com·Aug 17, 2026·matches: AstraZeneca · Tagrisso, Orpathys
ASTRAZENECA PLC · TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG
sec.gov·Aug 17, 2026·matches: AstraZeneca PLC · Tagrisso

Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026

Company disclosure·globenewswire.com·Aug 19, 2026·Trial readout·High materiality
CompaniesInfex TherapeuticsAssetsRESP-XDiseasesNon-cystic fibrosis bronchiectasis
2 sources — primary and 1 also reporting
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Primary·globenewswire.com·Aug 19, 2026
Infex Therapeutics to present new RESP-X Phase IIa data in late-breaking session at ERS Congress 2026
Trade press·biospace.com·Aug 19, 2026